Custom-Made vaccine aims to stop lung cancer recurrence
NCT ID NCT07683832
First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time
Summary
This study tests a personalized cancer vaccine, made specifically for each patient, to see if it is safe and can help prevent non-small cell lung cancer from coming back after surgery. The vaccine is given alone or together with an immunotherapy drug called toripalimab. The trial involves about 50 adults who have had their lung cancer surgically removed and are receiving standard post-surgery therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- personalized cancer vaccine (ABO2109) and toripalimab (anti-PD-1 antibody)
- What this could lead to
- If successful, this approach could offer a new way to prevent lung cancer from returning after surgery by training the immune system to recognize and attack remaining cancer cells.
- What could go wrong
- This is an early-phase trial with only 50 participants, so results may not apply broadly. The vaccine is personalized, making it complex and costly, and side effects from immune activation or the combination therapy are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Targeted drug LDK378 takes aim at rare ROS1-driven lung cancer
- Radiation and immunotherapy combo before lung cancer surgery shows promise in early trial
- New study aims to tame cholesterol side effect of lung cancer drug
- New pill targets Hard-to-Treat cancers with a specific gene mutation
- Can a drug stop muscle loss in lung cancer? new trial aims to find out
- New radiation 'Smart Bomb' targets Hard-to-Treat cancers in early trial